Skip to main content Skip to office menu Skip to footer
Capital IconMinnesota Legislature

Health and Human Services Policy

SEVENTH MEETING

2019-2020 Regular Session - Tuesday, February 5, 2019

STATE OF MINNESOTA SEVENTH MEETING
HOUSE OF REPRESENTATIVES NINETY-FIRST SESSION


HEALTH AND HUMAN SERVICES POLICY COMMITTEE

MINUTES

Representative Moran, Chair of the Health and Human Services Policy Committee, called the meeting to order at 2:33 PM on Tuesday, February 5, in Room 200 of the State Office Building. A quorum was present.

The Committee Legislative Assistant noted the roll.

Members present:
MORAN, Rena, Chair
MORRISON, Kelly, Vice Chair
ALBRIGHT, Tony
BACKER, Jeff
BAHNER, Kristin
EDELSON, Heather
FISCHER, Peter
FREIBERG, Mike
LIEBLING, Tina
LOEFFLER, Diane
MANN, Alice
NEU, Anne
PIERSON, Nels
PINTO, Dave
ROBBINS, Kristin

Members excused:
KIEL, Debra, Minority Lead
SCHOMACKER, Joe
SCHULTZ, Jennifer

Rep. Freiberg moved to adopt the minutes from January 30, 2019. THE MOTION PREVAILED.


Rep. Bahner moved HF149 be recommended to be re-referred to the Committee on
Commerce.

Rep. Bahner moved the A-1 amendment. THE MOTION PREVAILED.

Rep. Bahner presented HF149.

HF149 Testifier:
Jeff Lindoo, Past President, Minnesota Pharmacists Association

Rep. Bahner renewed the motion that HF149, as amended, be recommended to be re-referred to the Committee on Commerce. THE MOTION PREVAILED.


Chair Moran moved HF182 be recommended to be re-referred to the Committee on
Ways and Means.

Rep. Fischer moved the A-3 amendment. THE MOTION PREVAILED.

Rep. Lippert presented HF182.


HF182 Testifiers:
Rowan Mahon, Doctorate of Pharmacy Candidate, University of Minnesota
Cody Wiberg, Executive Director, Minnesota Board of Pharmacy

Chair Moran renewed the motion that HF182, as amended, be recommended to be re-referred to the Committee on Ways and Means. THE MOTION PREVAILED.


Chair Moran moved HF4 be recommended to be re-referred to the Committee on
Commerce.

Rep. Pinto moved the DE1-2 amendment. THE MOTION PREVAILED.

Rep. Lesch presented HF4.

HF4 Testifiers:
Attorney General Keith Ellison, State of Minnesota
Will Phillips, AARP State Director
Jessica Nyman, Minnesota Nurses Association
Rick Varco, SEIU Healthcare Minnesota
Stephen Schondelmeyer, University of Minnesota College of Pharmacy (Note: Testimony not on behalf of the University of Minnesota)
Brett Michelin, Association for Accessible Medicine
Kristina Moorhead, Senior Director of State Advocacy, PhRMA

Rep. Pierson moved the A-1 amendment.

A roll call was requested on the motion. The results are as follows:

AYES
ALBRIGHT, Tony
PIERSON, Nels

NAYS
MORAN, Rena
MORRISON, Kelly
BAHNER, Kristin
EDELSON, Heather
FISCHER, Peter
FREIBERG, Mike
LIEBLING, Tina
MANN, Alice
NEU, Anne
PINTO, Dave
ROBBINS, Kristin

There being 2 AYES and 11 NAYS, THE MOTION FAILED.


Chair Moran renewed the motion that HF4, as amended, be recommended to be re-referred to the Committee on Commerce.

A roll call was requested on the motion. The results are as follows:

AYES
MORAN, Rena
MORRISON, Kelly
BAHNER, Kristin
EDELSON, Heather
FISCHER, Peter
FREIBERG, Mike
LIEBLING, Tina
LOEFFLER, Diane
MANN, Alice
PINTO, Dave

NAYS
ALBRIGHT, Tony
BACKER, Jeff
PIERSON, Nels
NEU, Anne
ROBBINS, Kristin

There being 10 AYES and 5 NAYS, THE MOTION PREVAILED.


The meeting adjourned at 5:15 PM.




Representative Rena Moran, Chair



Alyssa Fritz, Committee Legislative Assistant

More Info On This Meeting..
Bills Added:
  • HF149 (Bahner) - Health plan company prohibited from contractually preventing a pharmacist from informing a patient of a price differential.
  • HF182 (Lippert) - Prescription drug repository program established, and money appropriated.
  • HF4 (Lesch) - Drug manufacturer or wholesale distributor prohibited from charging unconscionable prices for prescription drugs; Board of Pharmacy, commissioner of human services, and health plan companies required to notify the attorney general of certain prescription drug price increases; attorney general authorized to take action against drug manufacturers and wholesalers related to price increases; civil penalties imposed; and money appropriated.
Documents:

HF149 (Bahner) – Health plan company prohibited from contractually preventing a pharmacist from informing a patient of a price differential

HF182 (Lippert) – Prescription drug repository program established

HF4 (Lesch) – Manufacturer or wholesale drug distributor price gouging prohibited; Board of Pharmacy, commissioner of human services, and health plan companies allowed to notify attorney general of prescription drug price increases; attorney general authorized to obtain drug pricing information and take action against drug manufacturers and wholesalers; and civil penalties imposed.